Drugs Made In America Acquisition Corp. Units (NASDAQ:DMAAU) — Stock Price
Drugs Made In America Acquisition Corp. Units (NASDAQ:DMAAU) is currently trading at $10.79 USD, down 0.87% today. Over the past 52 weeks, shares have ranged between $10.30 and $11.70. This page tracks Drugs Made In America Acquisition Corp. Units's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see DMAAU company net worth.
Drugs Made In America Acquisition Corp. Units (DMAAU) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Drugs Made In America Acquisition Corp. Units's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Drugs Made In America Acquisition Corp. Units Income Statement — Revenue, Profit & Earnings by Year
Drugs Made In America Acquisition Corp. Units's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 |
|---|---|
| Total Revenue | $0.00 |
| Cost of Revenue | — |
| Gross Profit | — |
| Research & Development | — |
| SG&A | $2.82 Million |
| Total Operating Expenses | $2.82 Million |
| Operating Income | $-2.82 Million |
| EBITDA | $-2.82 Million |
| EBIT | — |
| Interest Expense | — |
| Income Before Tax | $5.94 Million |
| Income Tax Expense | — |
| Net Income | $5.94 Million |
Drugs Made In America Acquisition Corp. Units Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Drugs Made In America Acquisition Corp. Units's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Total Assets | $239.92 Million | $550.82 |
| Total Current Assets | $12.19K | $4.99K |
| Cash & Equivalents | — | — |
| Short-term Investments | — | $1.35K |
| Net Receivables | — | — |
| Inventory | — | — |
| Property, Plant & Equipment | — | — |
| Goodwill | — | — |
| Total Liabilities | $7.28 Million | $795.67 |
| Total Current Liabilities | $376.17K | $795.67 |
| Long-term Debt | — | — |
| Net Debt | $-6.14K | $660.97 |
| Total Stockholder Equity | $232.64 Million | $-244.00 |
| Retained Earnings | $-7.27 Million | $-279.00 |
Drugs Made In America Acquisition Corp. Units Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Drugs Made In America Acquisition Corp. Units generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 |
|---|---|---|
| Operating Cash Flow | $-539.19K | $-172.26K |
| Capital Expenditures | $0.00 | $5.00 |
| Free Cash Flow | $-539.19K | $-295.00 |
| Investing Cash Flow | $-231.15 Million | — |
| Financing Cash Flow | $231.69 Million | $173.62K |
| Dividends Paid | — | — |
| Stock-Based Compensation | — | — |
| Depreciation | — | — |
| Change in Cash | $4.79K | $1.35K |
Drugs Made In America Acquisition Corp. Units Earnings History — EPS Actual vs. Analyst Estimates
Track Drugs Made In America Acquisition Corp. Units's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | 0.01 | — | — |
| Nov 18, 2025 | 0.07 | — | — |
| Aug 14, 2025 | 0.07 | 0.00 | — |
| May 20, 2025 | 0.05 | 0.00 | — |
| Mar 31, 2025 | -0.03 | 0.00 | — |